How well do patients pursuing anti‐amyloid antibody therapies for Alzheimer's disease adhere to guidelines for promoting brain health?

A mix of pharmacologic and lifestyle interventions will likely result in the best outcomes in AD. In this sample of very motivated AD patients pursuing AATs, a sizeable portion were not fully adhering to brain health guidelines for reducing risk of cognitive decline. Many of the factors not optimally followed are also recommended for vascular health. These results highlight a critical gap in enhancing care for patients with underlying AD. Healthcare systems must establish more effective strategies and concrete interventions for addressing modifiable risk factors. Moreover, better systems are needed to ensure relevant, actionable patient data related to brain health (e.g., HbA1c, LDL) are collected and updated in the EMR.